Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts (NCT07139106)
Dynorphin/Kappa Opioid Receptor Signaling Role in Ketamine's Anti-suicidal Ideation Effect
🩺 Plain-English Summary (8th-Grade Level)
This study explores how stress, suicidal thoughts, and ketamine's effects are connected in people with major depressive disorder. Stress increases the risk for suicidal thoughts, but the biological basis is unclear. Ketamine may help reduce suicidal thoughts by affecting stress-linked brain systems. This study will use smartphone tracking to monitor real-time responses to stress and positron emission tomography (PET) brain scans to study how ketamine affects brain pathways related to stress and suicidal thoughts in depressed individuals.
Who can join: Review the eligibility criteria below.
Location: New York State Psychiatric Institute — New York, New York
Age range: 18 Years to 59 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- New York State Psychiatric Institute — New York, New York
📞 Contact the Study Coordinator
Phone: (646) 774-7608
Email: BartlettMINDResearch@nyspi.columbia.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Major Depressive Disorder (MDD)
- Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression — Arlington, Texas
- Neuroimaging Markers of Midlife Depression and Cognitive Behavioural Therapy (CBT) — Toronto, Ontario
- Ketogenic Diet and Neuromodulation in Treatment Resistant Depression — Toronto, Ontario
- REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness — Greenwich, Connecticut
- Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder — Toronto, Ontario
Explore by condition: All Major Depressive Disorder (MDD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.